Michael Folkert is an Oncology physician affiliated with University of Washington. OpenAlex indexes 174 publications with 2,519 citations (h-index 28); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1959 NE Pacific St.
Seattle, WA 981950001
Telephone
206-520-5000Provider last certified this registry record 6 Aug 2024.
Clinical trials
- High Dose Rate Brachyablation of Primary Liver Lesions
Sponsor: University of Texas Southwestern Medical Center
- Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer
Sponsor: University of Texas Southwestern Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Telix PharmaceuticalsProgram year20251 payment
- Boston Scientific CorporationProgram year20251 payment
- Boston Scientific CorporationProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
61.3%alpha-Adrenergic Blocker39.8%Tamsulosin Hcl100%Part D≥40 patientsCholinergic Muscarinic Antagonist15%Oxybutynin Chloride Er50%Solifenacin Succinate50%Part D<11 patients+ 1 more class in this area
Cancer & immunology
19.2%Androgen Receptor Inhibitor11.3%Bicalutamide100%Part D≥17 patientsGonadotropin Releasing Hormone Receptor Antagonist7.9%Orgovyx100%Part D<11 patientsCardiovascular
9.8%alpha-Adrenergic Blocker9.8%Doxazosin Mesylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes
International Journal of Radiation Oncology*Biology*Physics
2022 - SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial
International Journal of Radiation Oncology*Biology*Physics
2021 - Exploratory ensemble interpretable model for predicting local failure in head and neck cancer: the additive benefit of CT and intra-treatment cone-beam computed tomography features
Quantitative Imaging in Medicine and Surgery
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Neal Futran, MD, DMD
University of Washington
Elizabeth Swisher
University of Washington
David Tirschwell
University of Washington
Elaine Peskind, MD
University of Washington
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”